NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=106639&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

文章核心观点 - 根据诉讼,在整个Class Period期间,被告做出了虚假和/或误导性陈述,和/或未能披露:(1)botensilimab和balstilimab的联合疗法疗效低于被告所宣称的;(2)因此,botensilimab和balstilimab的临床结果以及监管和商业前景被夸大了;(3)因此,Agenus公司的公开声明在所有相关时期都存在重大虚假和误导性。[3] - 当真实情况进入市场时,诉讼称投资者遭受损失。[3] 公司概况 - Agenus Inc.是一家生物制药公司,专注于开发免疫肿瘤疗法。[1][3] - 公司正在开发两种药物:botensilimab(一种用于治疗胰腺癌和黑色素瘤的抗原4阻断性抗体,处于II期临床试验)和balstilimab(一种用于治疗二线宫颈癌的抗PD-1拮抗剂,已完成II期临床试验)。[3] 诉讼情况 - 该集体诉讼针对2023年1月23日至2024年7月17日期间购买Agenus证券的投资者。[1] - 投资者可以通过无需支付任何费用或成本的或有费用安排获得赔偿。[1] - 如果投资者希望担任首席原告,必须在2024年11月5日之前向法院提出申请。[1] - 该集体诉讼已经提起,投资者可以加入。[1]

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024. Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. and internationally. Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist th ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

文章核心观点 - 根据诉讼,公司在2023年1月23日至2024年7月17日期间做出了虚假和/或误导性陈述,并且未能披露以下信息[3]: 1) 公司正在开发的两种药物botensilimab和balstilimab的联合疗法疗效低于公司此前向投资者宣称的水平 2) 因此,botensilimab和balstilimab的临床结果、监管和商业前景都被夸大了 3) 公司的公开声明在相关时期都存在重大虚假和误导 公司概况 - 公司是一家全球性投资者权益法律公司,专注于证券集体诉讼和股东衍生诉讼[2] - 公司在2017年证券集体诉讼和和解方面排名第一,并在2013年以来连续4年位列前4名,为投资者收回了数亿美元[2] - 2019年公司单独为投资者赢得了4.38亿美元的和解金,2020年公司创始合伙人Laurence Rosen被评为原告律师界的泰坦[2] 诉讼信息 - 公司提醒2023年1月23日至2024年7月17日期间购买Agenus公司(纳斯达克代码:AGEN)证券的投资者,2024年11月5日是提出集体诉讼的最后期限[1] - 如果在上述期间购买了Agenus公司的证券,投资者可能有资格获得赔偿,无需支付任何费用或成本[1] - 投资者可以通过https://rosenlegal.com/submit-form/?case_id=28683或致电Phillip Kim律师(免费电话866-767-3653)获取更多信息[4]

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104517&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104025&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

文章核心观点 - 公司是一家临床阶段生物技术公司,专注于开发免疫肿瘤产品 [1] - 公司正在开发两款主要产品候选药物:balstilimab和botensilimab [1] - 公司宣称这两款药物的临床结果和监管前景被夸大了,实际疗效不如预期 [2][3] 公司概况 - 公司在美国和国际市场开展业务 [1] - 公司正在开发balstilimab和botensilimab两款免疫肿瘤产品候选药物 [1] - balstilimab是一种抗PD-1拮抗剂,已完成二线宫颈癌的II期临床试验 [1] - botensilimab(AGEN1181)是一种CTLA-4阻断抗体,正在进行胰腺癌和黑色素瘤的II期临床试验 [1] 公司业绩和前景 - 公司宣称balstilimab和botensilimab的联合疗法疗效不如预期 [2][3] - 公司的临床结果、监管前景和商业前景被夸大了 [2][3] - 公司的公开声明在相关时期存在重大虚假陈述 [2][3] - 公司在与FDA的"临床二期末期"会议上被告知不应提交加速批准申请,因为客观缓解率可能无法转化为生存获益 [3] - 公司股价在此消息公布后大跌58.83% [3]

NEW YORK, Sept. 20, 2024 /PRNewswire/ --, September 20, 2024 – Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/agenus-lawsuit-sub ...